Application of Lidocaine intravenous injection in Remimazolam anesthesia induction

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066806

Enrollment

Unknown

Registered

2022-12-19

Start date

2023-01-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

clinical anesthesia

Interventions

group1:Remimazolam+normal saline

group2:Remimazolam + Lidakine

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Patients under general anesthesia with selective tracheal intubation 2.Aged 18 to 65 years old 3.Body mass index (BMI)8-24kg/m2 4.American Society of Anesthesiology (ASA) Class ?-? 5.There were no signs associated with difficult airway

Exclusion criteria

Exclusion criteria: 1.Long-term use of antiarrhythmic drugs or beta-blockers 2.Implant a pacemaker 3.Patients with pregnancy 4.Patients with mental illness and cognitive impairment 5.Long-term use of non-steroidal anti-inflammatory drugs, narcotic analgesics, or sedatives

Design outcomes

Primary

Measure	Time frame
Cycle fluctuations;	—

Countries

China

Contacts

Public ContactRan Ran

Shiyan City People's Hospital, Hubei Province

ranran1145@163.com+86 18671910918

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026